EP1061908A4 - ASSOCIATED THERAPY FOR ACUTE CORONARY ISCHEMIC SYNDROME AND RELATED DISORDERS - Google Patents

ASSOCIATED THERAPY FOR ACUTE CORONARY ISCHEMIC SYNDROME AND RELATED DISORDERS

Info

Publication number
EP1061908A4
EP1061908A4 EP99911208A EP99911208A EP1061908A4 EP 1061908 A4 EP1061908 A4 EP 1061908A4 EP 99911208 A EP99911208 A EP 99911208A EP 99911208 A EP99911208 A EP 99911208A EP 1061908 A4 EP1061908 A4 EP 1061908A4
Authority
EP
European Patent Office
Prior art keywords
related disorders
acute coronary
ischemic syndrome
associated therapy
coronary ischemic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99911208A
Other languages
German (de)
French (fr)
Other versions
EP1061908A1 (en
Inventor
Steven A Nichtberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815857.9A external-priority patent/GB9815857D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1061908A1 publication Critical patent/EP1061908A1/en
Publication of EP1061908A4 publication Critical patent/EP1061908A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP99911208A 1998-03-13 1999-03-09 ASSOCIATED THERAPY FOR ACUTE CORONARY ISCHEMIC SYNDROME AND RELATED DISORDERS Withdrawn EP1061908A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7790098P 1998-03-13 1998-03-13
US77900P 1998-03-13
GB9815857 1998-07-21
GBGB9815857.9A GB9815857D0 (en) 1998-07-21 1998-07-21 Combination therapy for treating preventing or reducing the risks associated with acute coronary ischemic syndrome and related conditions
PCT/US1999/005063 WO1999045913A1 (en) 1998-03-13 1999-03-09 Combination therapy and composition for acute coronary ischemic syndrome and related conditions

Publications (2)

Publication Number Publication Date
EP1061908A1 EP1061908A1 (en) 2000-12-27
EP1061908A4 true EP1061908A4 (en) 2007-01-24

Family

ID=26314085

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99911208A Withdrawn EP1061908A4 (en) 1998-03-13 1999-03-09 ASSOCIATED THERAPY FOR ACUTE CORONARY ISCHEMIC SYNDROME AND RELATED DISORDERS

Country Status (4)

Country Link
EP (1) EP1061908A4 (en)
JP (1) JP2002506024A (en)
CA (1) CA2322824A1 (en)
WO (1) WO1999045913A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US7608640B2 (en) 1999-03-02 2009-10-27 Jallal Messadek Glycine betaine and its use
US6794412B1 (en) 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
EA200100966A1 (en) * 1999-03-11 2002-02-28 Дюпон Фармасьютикалз Компани TREATMENT OF THROMBOSIS BY THE COMBINED APPLICATION OF THE INHIBITOR OF THE FACTOR Xa AND ASPIRIN, THE ACTIVATOR OF A TISSUE PLASMINOGEN (TPA), ANTAGONIST GPIIB / IIIA, A LOW-MOLECULAR HEPARIN OR HEPARIN
CA2432642A1 (en) 2000-12-21 2002-08-08 Subhash P. Khanapure Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use
BE1015608A6 (en) 2003-07-15 2005-06-07 Messadek Jallal TREATMENT arteritis.
ATE487494T1 (en) * 2002-11-25 2010-11-15 Jallal Messadek BETAIN AND SALICYLIC ACID COMPOSITIONS
JP2004189711A (en) * 2002-12-11 2004-07-08 Raul Altman Use of meloxicam in combination with antiplatelet for treatment of acute coronary syndrome and related condition
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2006050581A2 (en) 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
WO2006086856A1 (en) 2005-02-15 2006-08-24 Messadek, Jallal Combination therapeutic compositions and method of use
CN101180073A (en) 2005-04-27 2008-05-14 贾拉尔·梅萨德克 insulin combination

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2105988A (en) * 1981-09-18 1983-04-07 Rocador Sa Anti-platelet aggregation dipyridamole with Al aspirin
WO1997021445A1 (en) * 1995-12-12 1997-06-19 Omeros Medical Systems, Inc. Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis
WO1997029753A1 (en) * 1996-02-19 1997-08-21 Sanofi New associations of active principles containing clopidogrel and an antithrombotic agent
WO1997038986A1 (en) * 1996-04-12 1997-10-23 G.D. Searle & Co. Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors
WO1997044027A1 (en) * 1996-05-17 1997-11-27 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
WO1997044028A1 (en) * 1996-05-17 1997-11-27 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
WO1997045420A1 (en) * 1996-05-31 1997-12-04 Merck & Co., Inc. Process for making phenyl heterocycles useful as cox-2 inhibitors
WO1998000416A1 (en) * 1996-07-03 1998-01-08 Merck & Co., Inc. Process of preparing phenyl heterocycles useful as cox-2 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5239113A (en) * 1991-10-15 1993-08-24 Monsanto Company Substituted β-amino acid derivatives useful as platelet aggregation inhibitors and intermediates thereof
US5250679A (en) * 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
UA57002C2 (en) * 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. (methylsulfonyl)phenyl-2-(5n)-furanon derivative, a pharmaceutical composition and a method for treatment
IT1276071B1 (en) * 1995-10-31 1997-10-24 Nicox Ltd ANTI-INFLAMMATORY ACTIVITY COMPOSITES
AU2202397A (en) * 1996-03-28 1997-10-17 G.D. Searle & Co. Iib/iiia antagonists co-administered with aspirin and/or heparin
HU224315B1 (en) * 1996-06-05 2005-07-28 Gyógyszerkutató Intézet Kft. Peptidyl-arginin-aldehyde derivatives of anticoagulant activity and pharmaceutical compositions containing them
BRPI9710372B8 (en) * 1996-07-18 2021-05-25 Merck Canada Inc compound, and, pharmaceutical composition.

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2105988A (en) * 1981-09-18 1983-04-07 Rocador Sa Anti-platelet aggregation dipyridamole with Al aspirin
WO1997021445A1 (en) * 1995-12-12 1997-06-19 Omeros Medical Systems, Inc. Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis
WO1997029753A1 (en) * 1996-02-19 1997-08-21 Sanofi New associations of active principles containing clopidogrel and an antithrombotic agent
WO1997038986A1 (en) * 1996-04-12 1997-10-23 G.D. Searle & Co. Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors
WO1997044027A1 (en) * 1996-05-17 1997-11-27 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
WO1997044028A1 (en) * 1996-05-17 1997-11-27 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
WO1997045420A1 (en) * 1996-05-31 1997-12-04 Merck & Co., Inc. Process for making phenyl heterocycles useful as cox-2 inhibitors
WO1998000416A1 (en) * 1996-07-03 1998-01-08 Merck & Co., Inc. Process of preparing phenyl heterocycles useful as cox-2 inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9945913A1 *

Also Published As

Publication number Publication date
EP1061908A1 (en) 2000-12-27
JP2002506024A (en) 2002-02-26
WO1999045913A1 (en) 1999-09-16
CA2322824A1 (en) 1999-09-16

Similar Documents

Publication Publication Date Title
EP1061908A4 (en) ASSOCIATED THERAPY FOR ACUTE CORONARY ISCHEMIC SYNDROME AND RELATED DISORDERS
EP0788359A4 (en) COMPOSITIONS USEFUL IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF VARIOUS REFRACTORY DISORDERS
FR2777192B1 (en) HERBAL COMPOSITION FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASES, BRONCHITIS AND RESPIRATORY DISORDERS AND PREPARATION METHOD THEREOF
EP1252329A4 (en) HYPOCRETINE AND HYPOCRETINE RECEPTORS FOR THE REGULATION OF SLEEP AND SLEEP DISORDERS
ITMI950497A0 (en) MICRONIZED SHOWER DEVICE FOR WASHING NASAL AND SURROUNDING CAVITIES
EP0765166A4 (en) RADIOMARK CONJUGATES OF ANNEXIN-GALACTOSE
ITBS990076A0 (en) VIBROSTIMULATOR FOR EFFECTIVE ACTION ON HEAD DISORDERS AND PAIN.
EP1284723A4 (en) COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA
FR2747548B1 (en) ROTATING STRUCTURE FOR THE PRESENTATION OF DECORATIVE ELEMENTS
NO982473D0 (en) 5'Deoxy-cytidine derivative
ITMI940884A0 (en) TOPICAL MEDICINAL PRODUCT WITH HEALING ACTIVITY
EP1060748A4 (en) MEDICATIONS FOR CORNEAL EPITHELIUM DISORDERS
EP1318822A4 (en) CELL-IMPLANTATION THERAPY FOR NEUROLOGICAL DISORDERS OR DISEASES
FR2715848B1 (en) Preparation of herbal topical emulsions.
FR2741903B1 (en) PORTION OF FENCE AND FENCE INCLUDING AT LEAST TWO OF SUCH PORTIONS
FR2720623B1 (en) Opening osteotomy plate.
FR2716623B1 (en) Use of a tricyclic derivative for obtaining medicaments intended for the treatment of mnemo-cognitive disorders.
USD375770S (en) Skater support device
FR2773074B1 (en) COMPOSITION BASED ON ALPHA-HYDROXY-ACIDS AND CERAMIDES FOR TOPICAL USE IN THE TREATMENT OF DERMATOLOGICAL CONDITIONS
FR2790388B1 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING A BENZAMIDE AND AT LEAST ONE ABSORPTION PROMOTER
EP1245236A4 (en) THERAPEUTIC AND PROPHYLACTIC PRODUCTS FOR CHRONIC HEPATICS
FR2737547B1 (en) PIPE FORMED OF AT LEAST TWO CONCENTRIC SHEATHES
BR9909868A (en) Paroxetine ascorbate
FR2732219B1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MALARIA, BASED ON A MEMBER OF THE CHONDROITINE-GLYCOSAMINOGLYCAN FAMILY
FR2715075B1 (en) Foot movement aid.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001013

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20001013;LT PAYMENT 20001013;LV PAYMENT 20001013;MK PAYMENT 20001013;RO PAYMENT 20001013;SI PAYMENT 20001013

A4 Supplementary search report drawn up and despatched

Effective date: 20061227

17Q First examination report despatched

Effective date: 20070810

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080221